Treatment of metastatic colorectal cancer: focus on panitumumab

Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tay, Rebecca Y, Wong, Rachel, Hawkes, Eliza A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484697/
https://www.ncbi.nlm.nih.gov/pubmed/26150735
http://dx.doi.org/10.2147/CMAR.S71821
_version_ 1782378706000412672
author Tay, Rebecca Y
Wong, Rachel
Hawkes, Eliza A
author_facet Tay, Rebecca Y
Wong, Rachel
Hawkes, Eliza A
author_sort Tay, Rebecca Y
collection PubMed
description Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.
format Online
Article
Text
id pubmed-4484697
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44846972015-07-06 Treatment of metastatic colorectal cancer: focus on panitumumab Tay, Rebecca Y Wong, Rachel Hawkes, Eliza A Cancer Manag Res Review Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC. Dove Medical Press 2015-06-24 /pmc/articles/PMC4484697/ /pubmed/26150735 http://dx.doi.org/10.2147/CMAR.S71821 Text en © 2015 Tay et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Tay, Rebecca Y
Wong, Rachel
Hawkes, Eliza A
Treatment of metastatic colorectal cancer: focus on panitumumab
title Treatment of metastatic colorectal cancer: focus on panitumumab
title_full Treatment of metastatic colorectal cancer: focus on panitumumab
title_fullStr Treatment of metastatic colorectal cancer: focus on panitumumab
title_full_unstemmed Treatment of metastatic colorectal cancer: focus on panitumumab
title_short Treatment of metastatic colorectal cancer: focus on panitumumab
title_sort treatment of metastatic colorectal cancer: focus on panitumumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484697/
https://www.ncbi.nlm.nih.gov/pubmed/26150735
http://dx.doi.org/10.2147/CMAR.S71821
work_keys_str_mv AT tayrebeccay treatmentofmetastaticcolorectalcancerfocusonpanitumumab
AT wongrachel treatmentofmetastaticcolorectalcancerfocusonpanitumumab
AT hawkeselizaa treatmentofmetastaticcolorectalcancerfocusonpanitumumab

Ejemplares similares